All HSJ Partners articles
View all stories of the same content type.
-
HSJ PartnersFrom long-term vision to in-year savings: digital solutions for today’s NHS
Digitally enabling solutions must deliver (in-year) cost savings as well as show demonstrable value in driving up productivity across the NHS
-
HSJ PartnersTackling health inequalities through people-led projects
Novartis Pharmaceuticals UK Ltd has provided sponsorship funding for this non-promotional piece. Novartis has had no input into the content, aside from agreement on the topic (tackling health inequalities through people-led projects).
-
HSJ PartnersFrom data to delivery: Why investing in personalised care is critical for system efficiency and health equity
For senior NHS leaders, addressing health inequalities is no longer just a moral imperative; it is a clinical and financial necessity
-
HSJ PartnersTransforming diagnostics for Somerset: Bridgwater CDC progresses at speed
As part of a long-term managed equipment service partnership with Somerset Foundation Trust, Ergéa has supported the development of the new £17.8m Bridgwater Community Diagnostic Centre (CDC), which will transform access to care in Bridgwater and across Somerset.
-
HSJ PartnersReimagining the Interstitial Lung Disease (ILD) Care Pathway - Boehringer Ingelheim article
This article was initiated, written and funded by Boehringer Ingelheim Interstitial lung disease (ILD) describes more than 200 rare and complex lung conditions. The most common fibrotic ILD is idiopathic pulmonary fibrosis (IPF), which has a median untreated life expectancy of just three to five ...
-
HSJ PartnersWe digitised decisions. Now we must digitise delivery.
The NHS holds more clinical data than ever, yet patient flow remains a daily struggle. Not because digital transformation has failed – but because we digitised decisions while leaving delivery analogue.
-
HSJ PartnersWhat can ctDNA tell us about a patient’s cancer?
Circulating tumour DNA (ctDNA) is transforming how we diagnose and treat complex cancers, particularly when clinical pathways are constrained by the speed, safety, and limitations of tissue biopsy.
-
HSJ PartnersDementia diagnosis: why patients can’t wait for the future
The government’s new vision for dementia diagnosis is ambitious: by 2029, more than 92 per cent of patients could receive a diagnosis within 18 weeks of referral, up from fewer than half today.
-
HSJ PartnersGetting classification right: Why remote monitoring safety depends on using the right level of medical device assurance
Remote monitoring has become an essential component of virtual wards and community-based care. As adoption accelerates, understanding medical-device classification is not a legal technicality, but a matter of clinical safety, governance and system integrity.
-
HSJ PartnersBeyond the attack count: Turning shared decision making into a reality in HAE care
For individuals living with hereditary angioedema (HAE) in the UK, their journey often begins with uncertainty, misdiagnosis and fragmented care.
-
HSJ PartnersClinically led, patient first: Redefining specialist care in dermatology
When lead clinician Andrew Morris reflects on the origins of the Sussex Community Dermatology Service (SCDS), one principle has guided every decision: putting the patient at the centre.
-
HSJ PartnersFostering co-production and tackling racism will build an NHS fit for all
The healthcare system’s current participation and co-production practice with diverse and marginalised communities remains, at best, extremely variable. At its worst, it can be actively harmful in its exclusion of some of the most marginalised voices in society.
-
HSJ PartnersShaping the future of respiratory care together
From addressing critical challenges to shaping innovative solutions: GSK’s medical head, general medicines, UK, Aruni Mulgirigama, shares her perspective on the future of respiratory care
-
HSJ PartnersSpotlighting the hidden challenges facing people living with blood cancer
This content has been developed and funded by Pfizer UK. Cancer is one of the biggest challenges of our lifetime. At Pfizer UK, we are determined to use our voice and position at the forefront of oncology care to help improve outcomes for cancer care and ensure no patient gets ...
-
HSJ PartnersA collaborative, prevention-first approach to tackling chronic kidney disease
This advertorial has been co-written and co-developed as part of the SPOT CKD collaborative working project between Boehringer Ingelheim, Hampshire and Isle of Wight Integrated Care Board, Health Innovation North East and North Cumbria, and the North East and North Cumbria ICB. The article has been funded by Boehringer ...
-
HSJ PartnersTransforming asthma care: Driving evidence-based practice in Bedfordshire, Luton and Milton Keynes ICB
Asthma affects 7.2 million people in the UK, with annual costs to the NHS estimated at £3bn.1,2
-
HSJ PartnersTackling health inequalities in a digital NHS: Making inclusion the national priority
As the NHS accelerates its digital transformation, the ambition is clear: the NHS App is set to become the digital front door for healthcare in England.
-
HSJ PartnersTime to end the postcode lottery in miscarriage care: why we need a national framework now
Irina Spirieva, general manager of Besins Healthcare UK and Ireland, explores the inconsistencies in miscarriage care across the UK and calls for national action to ensure all women receive timely, compassionate, and evidence-based support
-
HSJ PartnersUniversity hospitals key to unlocking UK’s £78bn healthcare innovation potential
Despite clear strengths in basic research and discovery, the UK struggles to translate innovation into clinical outcomes. The University Hospital Association and Boston Consulting Group explore how university hospitals can bridge this gap and deliver transformative benefits to patients, the NHS, and society more broadly.
-
HSJ PartnersBeyond the pilot: How NHS systems are embedding remote monitoring into everyday care
We’re at a turning point in the NHS. After years of pilots, remote monitoring is beginning to take hold at scale.